A lot of those people chose to receive the booster of the same vaccine that they received for their primary series.
Second, Moderna is gaining more traction with boosters than Pfizer-BioNTech or J&J are.A little over 25% of the number of fully vaccinated individuals receiving the primary series of the Moderna vaccine have received Moderna boosters.
For those who initially received the J&J vaccine, 42.5% so far have gone with the Moderna booster versus 31.2% for a Pfizer-BioNTech booster and only 26.2% for a J&J booster. .
I suspect that preliminary data showing that a mix-and-match combination of the Pfizer-BioNTech primary series and a Moderna booster provides a higher efficacy could also be making a difference to some extent.Singapore's minister of health even recently recommended that citizens in the country who initially received the Pfizer-BioNTech vaccine get the Moderna booster.
has already purchased enough doses from Moderna to meet the demand, including boosters.
What really matters for Moderna is how strong the longer-term demand will be for its COVID-19 vaccine.